Medullary breast carcinoma:: Prognostic implications of p53 expression

被引:11
作者
Dendale, R
Vincent-Salomon, A
Mouret-Fourme, E
Savignoni, A
Medioni, J
Campana, F
Vilcoq, JR
de la Rochefordière, A
Soussi, T
Asselain, B
de Cremoux, P
Fourquet, A
机构
[1] Inst Curie, Dept Radiotherapy, F-75248 Paris 05, France
[2] Inst Curie, Dept Tumor Biol, F-75248 Paris 05, France
[3] Inst Curie, Dept Biostat, F-75248 Paris 05, France
[4] Inst Curie, Genotoxicol Tumors Lab, F-75248 Paris 05, France
关键词
medullary breast carcinoma; TP53; gene; p53; protein; immunohistochemistry; prognosis;
D O I
10.1177/172460080301800202
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Medullary breast carcinoma (MBC) is a rare pathological type of breast cancer. The rate of p53 protein accumulation is higher in MBC than in common invasive ductal carcinoma. Whether this particular feature of MBC influences the outcome after treatment is unknown. We retrospectively analyzed the characteristics, treatment and outcome of 71 patients with MBC treated between 1981 and 1996. The median age was 51 years (range 27-81) and the median clinical tumor size was 25 mm (range 0-70 mm). Breast-conserving treatment was offered when possible: 55 patients had undergone a tumorectomy and radiotherapy while 16 patients had undergone a mastectomy. p53 protein accumulation was determined by immunohistochemistry on paraffin-embedded tumor specimens from 58/71 samples available for this study. The median follow-up for the 56 survivors was 113 months (range 30-241). The 10-year survival and metastasis-free survival rates were 81% and 81.4%, respectively. The local recurrence rate was 16.4%. The two factors predicting outcome were pathological axillary node involvement in the 60 patients who underwent axillary dissection and adjuvant chemotherapy. p53 accumulation was found in 33/58 patients (57%). p53 status was not predictive of survival nor of distant or local recurrences. We confirm that medullary breast carcinoma has a favorable prognosis despite its aggressive pathological features. p53 protein accumulation, found in the majority of MBCs, was not related to outcome.
引用
收藏
页码:99 / 105
页数:7
相关论文
共 39 条
  • [1] Barbareschi M, 1996, APPL IMMUNOHISTOCHEM, V4, P106
  • [2] IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN IN MAMMARY-CARCINOMA - AN IMPORTANT NEW INDEPENDENT INDICATOR OF PROGNOSIS
    BARNES, DM
    DUBLIN, EA
    FISHER, CJ
    LEVISON, DA
    MILLIS, RR
    [J]. HUMAN PATHOLOGY, 1993, 24 (05) : 469 - 476
  • [3] Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers
    Biganzoli, E
    Boracchi, P
    Daidone, MG
    Gion, M
    Marubini, E
    [J]. INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 1998, 13 (03) : 107 - 123
  • [4] Casey G, 1996, ONCOGENE, V13, P1971
  • [5] Charpin C, 1999, INT J ONCOL, V15, P285
  • [6] p53 mutation as a genetic trait of typical medullary breast carcinoma
    de Cremoux, P
    Salomon, AV
    Liva, S
    Dendale, R
    Bouchind'homme, B
    Martin, E
    Sastre-Garau, X
    Magdelenat, H
    Fourquet, A
    Soussi, T
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (07) : 641 - 643
  • [7] DOMAGALA W, 1993, AM J PATHOL, V142, P669
  • [8] Eisinger F, 1998, CANCER RES, V58, P1588
  • [9] Prognostic and predictive value of p53 and p21 in breast cancer
    Elledge, RM
    Allred, DC
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) : 79 - 98
  • [10] ELLEDGE RM, 1994, CANCER RES, V54, P3752